Tag
Indegene Limited
5 articles
Indegene Limited's recent Annual General Meeting highlighted a period of significant growth and strategic expansion. The company reported a robust 23.6% revenue increase to ₹35.1 billion for fiscal year 2026, alongside a profit after tax of ₹4.011 billion, and declared a final dividend of ₹2.25 per share. Further bolstering its capabilities, Indegene completed three strategic acquisitions, including BioPharm for approximately ₹882 crores, to enhance its AI and digital offerings. The appointment of Jill De Simone as an Independent Director, bringing extensive biopharmaceutical experience, signals a focus on strengthening corporate governance and supporting future growth initiatives.
Indegene FY26 Revenue Up 23.6% to ₹35.1B
Held 28th Annual General Meeting via video conference, presenting FY2025-26 financial results and strategic updates.
Reported revenue growth of 23.6% to ₹35,105 million with PAT of ₹4,011 million and
Indegene Appoints Jill De Simone Independent Director
Shareholders approved Jill De Simone's appointment as Independent Director at 28th AGM held August 13, 2026.
Her term is for three years from January 22, 2026 to January 21, 2029, following SEBI listi
Indegene 28th AGM Approves All 5 Resolutions
Indegene Limited held its 28th Annual General Meeting virtually on August 13, 2026, with all five proposed resolutions passing by requisite majority.
Shareholders approved the adoption of FY26 financi
Indegene Schedules August 19 Investor Meeting
Indegene Limited intimates a scheduled one-on-one investor meeting with Buoyant Capital in Mumbai on August 19, 2026.
The disclosure is made pursuant to SEBI Listing Obligations and Disclosure Require
Indegene 28th AGM Approves Dividend and Director Appointments
Indegene Limited held its 28th Annual General Meeting on August 13, 2026, via video conference to transact business including financial statements adoption.
Shareholders approved a final dividend of ₹